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In the world of diabetes management there is a lot be thankful for. Over the past three 
decades, excess mortality rates in people with diabetes relative to the general population have 
declined substantially in high-income countries such that those with diabetes are living longer 
than ever. That said, the gap in life expectancy remains at an average of ~ 6 years in those 
diagnosed with diabetes in middle age, with considerably more life years lost when diabetes 
presents much earlier in life [1]. This is an issue because the numbers presenting earlier are 
rising, leading to greater challenges in care. Part of this mortality benefit must arise from a 
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narrowing of the gap between the true onset of diabetes and actual clinical diagnosis, verified 
in part by lower retinopathy rates at diagnosis. However, the more recent (post 2000) benefits 
in mortality rates cannot have come from treatment of glucose alone; rather, substantial 
contributions from guidelines recommended targeting of blood cholesterol and blood pressure 
levels have been critical. In our meta-analysis of intensive glucose-lowering trials conducted 
in 2009 [2], the trial data suggested that more cardiovascular events were being prevented by 
lipid and blood pressure management. By contrast, these same intensive glucose-lowering 
trials did not lower overall mortality and, in some cases, there were signals for harm [3]. 
Whilst glucose control remained ‘king’ in diabetes care, and in many places still does, these 
results led to much consternation among the diabetes community. Regulators reacted by 
demanding that all novel diabetes agents undergo cardiovascular outcome trials. 
 
If we wind the clock forwards 10 years to the present day, it is remarkable how much the 
diabetes landscape has changed. As elegantly reviewed by Bain and expert diabetes 
colleagues from around England, Wales and North Ireland, multiple positive trials 
demonstrating the superiority of novel classes of diabetes agents for either cardiovascular or 
renal outcomes have emerged [4]. In some cases, total mortality was also reduced and 
extremely positive signals for the prevention of heart failure were noted [5]. All positive trials 
come either from the sodium–glucose cotransporter 2 (SGLT2) inhibitor class or the 
glucagon like peptide-1 receptor agonist (GLP-1RA) class of drugs [6]. These therapies are 
not without some side effects but overwhelmingly, if used with some degree of care and 
common clinical sense, their outcome benefits substantially outweigh potential harms. 
Consequently, as Bain and colleagues argue, given the benefits of these novel agents on hard 
outcomes (an absolute ‘must’ in the care of people with diabetes), many guidelines around 
the world upgraded the use of such drugs in their diabetes algorithms, with several directly 
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naming the initial successful drugs in each class (Empagliflozin and Liraglutide), although 
other drugs have since been added to this list. Most guidelines prioritized the use of such 
agents in people with existing cardiovascular disease, the group in which the majority of 
trials were conducted. That said, further results from newer trials in people with diabetes who 
are at elevated risk of cardiovascular disease have begun to emerge and more are imminent so 
that guidance can be further extended or nuanced as required. Notably, however, the 
prevention of heart failure or cardiovascular death, or prevention of meaningful renal 
outcomes seems to occur to broadly similar extents in people with existing cardiovascular 
disease or in those with multiple risk factors in the trials of SGLT2 inhibitors [6,7]. 
 
On the basis of these data, as well as positive results from cost-effectiveness analyses, Bain 
and colleagues suggest that even if some countries have not yet updated their diabetes 
guidelines, it is important for doctors to consider an individual’s cardiovascular risk when 
selecting their diabetes therapy. Many agree, as do I. In some respects, these authors are 
expressing a minor degree of frustration that their national guidelines seem to be lagging 
behind others, although it appears that this deficit will soon be rectified.  
 
Of course, newer drugs cost more money and doctors must be careful not to ‘break the bank’; 
some sensible ‘rationing’ of newer therapies must be in place. Nevertheless, if we return to 
the cost-effectiveness argument, Bain and colleagues correctly point out that current cost-
effective analyses of SGLT-2is and GLP-1RAs were based on reducing hyperglycaemia per 
se and did not consider their wider benefits on cardiovascular outcomes. Nor did the analyses 
consider the use of other healthcare resources, so we may be underestimating benefits. It 
would further be helpful if such analyses could better consider outcomes reported by the 
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person with diabetes, because although reducing the risk of hard outcomes is a must, more 
research is needed to determine how different drugs influence a person’s quality of life and 
capacity to work. In this respect, it can only be a plus that newer agents help lower weight – 
in some cases quite considerably – and do not increase hypoglycaemia risk per se.  
 
So, how are doctors reacting to this new evidence? It appears rather slowly for now [8]. The 
major issue is that diabetes is diagnosed on the basis of hyperglycaemia and so its treatment 
has fixated on such targets. Yet, these new trials have taught us several important points, 
including that some drugs developed to lower glucose have outcome benefits via mechanisms 
largely independent of glucose lowering per se. How do we know this? In several of the trials, 
the outcome benefits were evident regardless of any glucose lowering. Furthermore, we have 
learned that pathogenic pathways leading to common outcomes in diabetes go well beyond 
measurable hyperglycaemia, or other targeted risk factors; for example, we appear to have 
underestimated the importance of ‘hidden’ factors such haemodynamic perturbances, 
potentially critical to renal and heart failure outcomes [9]. Finally, it must now be obvious all 
to that one cannot predict the outcome benefits of new diabetes drugs on the basis of their 
effects on glucose or known cardiovascular risk factors, and only trials will lead us to the 
eventual truth. Trials can also uncover hidden risks or alleviate concerns on postulated risks.  
 
Where do we go from here? The landscape has changed so dramatically that many of us are 
failing to keep apace, and this is why we need guidelines. Even so, all doctors should be 
grateful to have in their toolbox diabetes agents that meaningfully lessen mortality and/or 
cardiovascular or cardiorenal risks. In short, the healthcare community needs to understand 
that the focus in care on reducing glucose alone is no longer appropriate; it is time for ‘old 
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dogs to learn new tricks’. Yes, glycaemia levels matter, but so does the choice of drug 
dependent on an individual’s risk characteristics, irrespective of any effects on glucose levels 
per se. This subtle shift in emphasis is not easy task and ‘education, education, education’ 
must be the mantra so that as many suitable people with diabetes as possible benefit. 
Hopefully, the forthcoming updated National Institute of Health and Care Excellence 
guidelines point the way.  
 
Finally, we must not forget that newer diabetes drugs are not the only game in town. Recent 
studies have reminded us that there are potential outcome benefits in diabetes prevention [10] 
and also merit in diabetes remission for some, perhaps many, early after their diagnosis [11]. 
Both interventions are cost-effective and it is surely better to prevent disease than treating it 
when advanced. Still, evidence-based benefits at both ends of the diabetes spectrum are 
welcome and add much more to our toolbox than ever before to help improve the lives of 
those with diabetes.  
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